FACACLASSIC

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.

Details on agency responses to committee recommendations can be found under the Performance Measures section for each committee in the fields “Agency Feedback” and “Agency Feedback Comment.”

HHS - 852 - Center for Substance Abuse Prevention Drug Testing Advisory Board - Authorized by Law

GENERAL INFORMATION

Committee Name	Center for Substance Abuse Prevention Drug Testing Advisory Board	Agency Name	Department of Health and Human Services
Fiscal Year	2025	Committee Number	852
Original Establishment Date	10/27/1986	Committee Status	Terminated
Actual Termination Date	4/1/2025	Committee URL	http://www.samhsa.gov/about-us/advisory-council...
Actual Merged Date		Presidential Appointments*	No
New Committee This FY	No	Max Number of Members*	unlimited
Terminated This FY	Yes	Designated Fed Officer Position Title*	Senior Toxicology Policy Advisor
Merged This FY		Designated Federal Officer Prefix
Current Charter Date	6/25/2024	Designated Federal Officer First Name*	Lisa
Date Of Renewal Charter	6/25/2026	Designated Federal Officer Middle Name
Projected Termination Date	4/1/2025	Designated Federal Officer Last Name*	Davis
Exempt From Renewal*	No	Designated Federal Officer Suffix
Specific Termination Authority	2025 Secretary Directive	Designated Federal Officer Phone*	(240) 276-1440
Establishment Authority*	Authorized by Law	Designated Federal Officer Fax*	(240) 276-2610
Specific Establishment Authority*	42 U.S.C. § 217a, Section 222 of the Public Health Service Act	Designated Federal Officer Email*	lisa.davis@samhsa.hhs.gov
Effective Date Of Authority*	10/27/1986
Exempt From EO 13875 Discretionary Cmte	Not Applicable
Committee Type*	Continuing
Presidential*	No
Committee Function*	Scientific Technical Program Advisory Board

RECOMMENDATION/JUSTIFICATIONS

Agency Recommendation*	Terminate
Legislation to Terminate Required	Not Applicable
Legislation Status	Not Applicable
How does cmte accomplish its purpose?*	The CSAP Drug Testing Advisory Board's recommendations are an essential prerequisite for implementation of new science into regulation and practice.The CSAP Drug Testing Advisory Board provides advice to the Assistant Secretary for Mental Health and Substance Use, SAMHSA, as the Agency responsible for establishing federal agency workplace drug testing policies in accordance with Executive Order 12564, based on an ongoing review of the direction, scope, balance, and emphasis of the Agency's drug testing activities and the drug testing laboratory certification program. The CSAP Drug Testing Advisory Board reviews SAMHSA's program for national laboratory certification for federal workplace drug testing programs as required by Public Law 100-71 and as described in the Mandatory Guidelines for Federal Workplace Drug Testing Programs. It recommends areas for emphasis or de-emphasis, new or changed directions, and mechanisms or approaches for implementing recommendations. The CSAP Drug Testing Advisory Board also reviews the science associated with alternate specimen matrices and new drugs of abuse and the methods necessary to detect their presence.
How is membership balanced?*	The CSAP Drug Testing Advisory Board consists of three nonvoting ex officio members who are officers or employees of the United States Government, as the Assistant Secretary for Mental Health and Substance Use, SAMHSA, determines necessary for the CSAP Drug Testing Advisory Board to effectively carry out its functions. The 10 public members are appointed by the Assistant Secretary, SAMHSA. Of the 10 appointed members, 8 are recognized as experts in either analytical forensic toxicology, in specimen collection procedures for regulated drug testing programs, and interpreting drug testing results. The appointed individuals should represent a variety of disciplines related to forensic drug testing, such as experience in a forensic drug testing laboratory, related academic research, toxicological research, the Medical Review Officer community, or technical expertise from other government agencies involved with drug testing issues, including military drug testing programs. Of the additional two appointed members, one shall represent users of SAMHSA’s certified drug testing laboratories and drug-free workplace programs and processes and one shall represent individuals tested in federal or federally-regulated workplace drug testing programs. All Board members who are not officers or employees (full-time or permanent part-time) of the United States Government shall serve as Special Government Employees. Appointments are made by paying close attention to experience and expertise as well as equitable gender representation, race/ethnicity representation, and geographic distribution. Board members advise SAMHSA executive leadership on policy and scientific and technical program development.
How frequent & relevant are cmte mtgs?*	CSAP Drug Testing Advisory Board convened three times during FY 2024. Four meetings are tentatively scheduled for fiscal year 2025. The CSAP Drug Testing Advisory Board was charged during this fiscal year with evaluating the scientific supportability of the hair matrix as an alternative specimen for the inclusion in the Federal Workplace Drug Testing Programs. That work has proved challenging and time intensive. The CSAP Drug Testing Advisory Board also received federal drug testing updates from the Department of Transportation, the Department of Defense, the Nuclear Regulatory Commission, and the Federal Drug-Free Workplace Programs. In addition, the CSAP Drug Testing Advisory Board will continue to assist the Agency in recommending revisions to the Mandatory Guidelines for testing alternative specimens in addition to current matrixes and additional Schedule II drugs, addressing the impact of new drugs of abuse in the workplace, and assessing the methods that are available to detect their use. The CSAP Drug Testing Advisory Board will review the Agency's National Laboratory Certification Program that was established as required by the Supplemental Appropriations Act of 1987 (Public Law 100-71) and as described in the Mandatory Guidelines. These meetings were relevant to carry out the board's functions.
Why advice can't be obtained elsewhere?*	The CSAP Drug Testing Advisory Board is composed of both scientific and professional members who provide advice to the Assistant Secretary for Mental Health and Substance Use on improving the quality of services for forensic workplace drug testing, assessing the science and technology used in drug analyses, improving the quality of related laboratory services and systems for drug testing, generating standards for laboratory certification for federal workplace drug testing programs, and guiding national policy in these areas. There is no existing committee or other alternative mechanism that can provide the same expert advice as that provided by the CSAP Drug Testing Advisory Board.
Why close or partially close meetings?	The closed portions of the Board's meetings involve discussions by the Board of proposed revisions to the Mandatory Guidelines for Federal Workplace Drug Testing Programs, unpublished and confidential research material, and the review of sensitive National Laboratory Certification Program information. These portions of the meetings are closed to the public as determined by the Assistant Secretary for Mental Health and Substance Use, SAMHSA, in accordance with 5 U.S.C. 552b(c)(9)(B) and 5 U.S.C. App. 2, Section 10(d).
Recommendation Remarks	2025 Secretary Directive-Elimination of Federal Advisory Committees Within the Department of Health and Human Services, Terminated 04.01.2025. EO 14217 Reducing the Scope of the Federal Bureaucracy.

PERFORMANCE MEASURES

Outcome Improvement To Health Or Safety*	Yes	Action Reorganize Priorities*	Yes
Outcome Trust In Government	Yes	Action Reallocate Resources	No
Outcome Major Policy Changes	Yes	Action Issued New Regulations	Yes
Outcome Advance In Scientific Research	Yes	Action Proposed Legislation	No
Outcome Effective Grant Making	No	Action Approved Grants Or Other Payments	No
Outcome Improved Service Delivery	Yes	Action Other	No
Outcome Increased Customer Satisfaction	Yes	Action Comment	NA
Outcome Implement Laws/Reg Requirements	Yes	Grants Review*	No
Outcome Other	No	Number Of Grants Reviewed	0
Outcome Comment	NA	Number Of Grants Recommended	0
Cost Savings*	Unable to Determine	Dollar Value Of Grants Recommended	$0.00
Cost Savings Comment	It is extremely difficult to determine the cost savings associated with identifying a federal employee as positive for an illicit substance.	Grants Review Comment	NA
Number Of Recommendations*	38	Access Contact Designated Fed. Officer*	Yes
Number Of Recommendations Comment	From FY 1994 to FY 2024, the CSAP DTAB produced 38 recommendations. The Oral Fluid Mandatory Guidelines was finalized and released in the Federal Register on October 25, 2019 with effective date of January 1, 2020. Current work is being conducted on the proposed Hair Mandatory Guidelines.	Access Agency Website	Yes
% of Recs Fully Implemented*	97.00%	Access Committee Website	Yes
% of Recs Fully Implemented Comment	Since the beginning of the Board, approximately 97% of the Board's recommendations have been fully implemented without any changes. These recommendations concerned revisions to the Mandatory Guidelines, urine and oral fluid collection handbooks, medical review officer manuals, and other National Laboratory Certification Program documents and policies.	Access GSA FACA Website	Yes
% of Recs Partially Implemented*	3.00%	Access Publications	Yes
% of Recs Partially Implemented Comment	The Board's recommendations regarding changes in the scientific and administrative aspects of the Federal Workplace Drug Testing Programs are occasionally modified by the Department based on comments received from other Health and Human Services agencies; other federal departments, including the Department of Transportation, the Department of Defense, and the Nuclear Regulatory Commission; and the Office of Management and Budget. The hair recommendation is in the proposed process.	Access Other	No
Agency Feedback*	Yes	Access Comment	N/A
Agency Feedback Comment*	Feedback is provided to the Board members on the actions taken by the Agency on the Board's recommendations at each Board meeting, by e-mailing documents to the Board members. Additionally, when policies are implemented, Board members are provided copies. The public can obtain information on agency feedback about recommendations recorded in the meeting minutes that are open to the public.	Narrative Description*	The Board provides advisory recommendations regarding improvements in the scientific aspects of forensic workplace drug testing, thereby, impacting on the Agency's efforts to prevent substance abuse among federal employees.

COSTS

1. Payments to Non-Federal Members*		1. Est Paymnts to Non-Fed Membrs Nxt FY*
2. Payments to Federal Members*		2. Est. Payments to Fed Members Next FY*
3. Payments to Federal Staff*		3. Estimated Payments to Federal Staff*
4. Payments to Consultants*		4. Est. Payments to Consultants Next FY*
5. Travel Reimb. For Non-Federal Membrs*		5. Est Travel Reimb Non-Fed Membr nxtFY*
6. Travel Reimb. For Federal Members*		6. Est Travel Reimb For Fed Members*
7. Travel Reimb. For Federal Staff*		7. Est. Travel Reimb to Fed Staf Nxt FY*
8. Travel Reimb. For Consultants*		8. Est Travel Reimb to Consltnts Nxt FY*
10. Other Costs		10. Est. Other Costs Next FY*
11. Total Costs	$0.00	11. Est. Total Next FY*	$0.00
Date Cost Last Modified	3/14/2025 9:52 AM	Est. Fed Staff Support Next FY*
Federal Staff Support (FTE)*		Est Cost Remarks
Cost Remarks

Interest Areas

Category Area Applied Science Applied Sciences Basic Science Chemistry Food and Drugs Food and Drugs Government Federal Government Health Safety Justice Drug Abuse Policy and Enforcement Prevention

Custom Links

Committee Level Reports